Summary
This retrospective cohort study used the TriNetX research network to identify adult patients with pre-existing psychiatric disorders and non-hospitalized COVID-19 from 1 January 2022 to 1 May 2023. After exclusions, 1,031,524 patients were included: 9,426 in the molnupiravir group and 1,022,098 in the non-molnupiravir group before propensity score matching; after matching, two groups of 9,421 patients each were analysed. Molnupiravir was compared with not receiving molnupiravir; treatment duration was not reported. Outcomes were the composite of all-cause hospitalization or death within 30 days and post-COVID-19 conditions up to a year after diagnosis. During the 30-day follow-up, the treated group had a reduced risk of hospitalization or mortality (HR, 0.760; 95% CI, 0.665–0.869), and the composite outcome was lower than in the untreated group (log-rank test, p < 0.001). For post-COVID-19 conditions during the 1-year follow-up, the reported HRs included chest/throat pain (HR, 0.615; 95% CI, 0.543–0.696), abnormal breathing (HR, 0.761; 95% CI, 0.687–0.884), abdominal symptoms (HR, 0.748; 95% CI, 0.674–0.831), fatigue (HR, 0.718; 95% CI, 0.638–0.808), headache (HR, 0.753; 95% CI, 0.665–0.852), cognitive symptoms (HR, 0.769; 95% CI, 0.630–0.940), myalgia (HR, 0.647; 95% CI, 0.530–0.789), cough (HR, 0.867; 95% CI, 0.770–0.978), and palpitation (HR, 0.641; 95% CI, 0.534–0.770). Harms were not reported. The authors state limitations including possible coding errors, residual confounding, and not assessing the effect for each specific psychiatric disorder.